Optinose Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
March 03, 2021 07:00 ET
|
Optinose, Inc.
Company reports fourth quarter and full year 2020 XHANCE net revenue of $15.6 million and $48.4 million Full year 2020 XHANCE prescriptions increased 70% compared to full year 2019 Company...
Optinose to Highlight Data at Two Upcoming Scientific Meetings
October 03, 2018 07:00 ET
|
OptiNose, Inc.
YARDLEY, Pa., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Named a 2018 Best Place to Work by Philadelphia Business Journal
July 02, 2018 17:11 ET
|
OptiNose, Inc.
YARDLEY, Pa., July 02, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Pricing of Public Offering of Common Stock
June 06, 2018 20:21 ET
|
OptiNose, Inc.
YARDLEY, Pa., June 06, 2018 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public...
Optinose Announces Launch of Public Offering of Common Stock
June 04, 2018 16:56 ET
|
OptiNose, Inc.
YARDLEY, Pa., June 04, 2018 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission...
Optinose Reports First Quarter 2018 Financial Results and Recent Operational Highlights
May 14, 2018 07:00 ET
|
OptiNose, Inc.
Optinose confirms retail pharmacy availability of XHANCE commenced in early April Company reports more than 1,300 physicians have prescribed XHANCE through the Xperience program YARDLEY, Pa., May ...
Optinose to Report First Quarter 2018 Financial Results and Corporate Updates on May 14, 2018
May 07, 2018 08:00 ET
|
OptiNose, Inc.
YARDLEY, Pa., May 07, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the...
Optinose CEO Peter Miller and President/COO Ramy Mahmoud Named EY Entrepreneur of the Year 2018 Finalists in the Greater Philadelphia Area
April 23, 2018 16:01 ET
|
OptiNose, Inc.
YARDLEY, Pa., April 23, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Named Emerging Company of the Year by Life Sciences Pennsylvania
March 15, 2018 16:01 ET
|
OptiNose, Inc.
YARDLEY, Pa., March 15, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Highlights
March 13, 2018 07:00 ET
|
OptiNose, Inc.
Optinose expects early April availability of XHANCE in retail pharmacies XHANCE Xperience program launched in early March YARDLEY, Pa., March 13, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a...